Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

Video

In Partnership With:

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non—small cell lung cancer (NSCLC).

Data on second-line therapy with pembrolizumab after chemotherapy showed a lower response rate of approximately 21%. Brahmer suggests that receiving chemotherapy before pembrolizumab may not be beneficial, particularly for patients who express high levels of PD-L1.

Many in the field are moving away from single-agent pembrolizumab, says Brahmer, specifically in the treatment of patients with nonsquamous cell histologies. However, cohort G of the KEYNOTE-021 study showed higher response rates with the combination of pembrolizumab, carboplatin and pemetrexed compared with carboplatin and pemetrexed alone in NSCLC.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD